Kristin Van Goor

Company: Takeda Pharmaceutical

Job title: Executive Director & Head of Global Regulatory Policy & Innovation

Seminars:

12:00 PM Panel Discussion: Defining Surrogate Endpoints for Rare Kidney Disease 12:00 pm

Analyzing lessons learned regarding surrogate endpoints for rare and genetic kidney diseases Examining the application of PLA IIR as a potential endpoint for Membranous Nephropathy Outlining the unique considerations relating to demonstrating efficacy in transplant patients with disease recurrenceRead more

day: Conference Day 1

5:00 PM Panel: Discussing the Evolving Role of Biomarkers for Therapeutic Differentiation in a Crowded Landscape 5:00 pm

Exploring the increasing need for biomarkers that can meaningfully differentiate the clinical impact of emerging renal therapies for rare kidney diseases Discussing the repurposing of established biomarkers in new contexts to reveal subtle and clinically relevant differences between new treatments Addressing opportunities and challenges in utilizing novel biomarkers in rare kidney disease trials to demonstrate…Read more

day: Conference Day 1